Should epidermal growth factor receptor-tyrosine kinase inhibitor be continued beyond progressive disease?

Case Reports in Oncology

Volumn 4, Issue 3, 2011, Pages 470-474

  Kim, Young Hak ^a   Fukuhara, Akiko ^a   Mishima, Michiaki ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Acquired resistance; Continuation; EGFR mutation; Epidermal growth factor receptor tyrosine kinase inhibitor; Non small cell lung cancer; Progressive disease

Indexed keywords

GEFITINIB; NAVELBINE; PEMETREXED;

ADULT; ARTICLE; BRAIN RADIATION; BRONCHOSCOPY; CANCER GROWTH; CANCER MORTALITY; CANCER REGRESSION; CASE REPORT; DISEASE COURSE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG METASTASIS; MALE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84855319677     PISSN: None     EISSN: 16626575     Source Type: Journal    
DOI: 10.1159/000332758     Document Type: Article

References (11)

1. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al.: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
2. Riely GJ, Kris MG, Zhao B, Akhurst T, Minton DT, Moore E, et al.: Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 2007;13:5150-5155. (Pubitemid 47502083)
3. Van Oosterom AT, Dumez H, Desai J, Stroobants S, Van Den Abbeele AD, Clement P, et al.: Combination signal transduction inhibition: a phase I/II trial of the oral mTOR-inhibitor everolimus (E, RAD001) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM. ASCO Meeting Abstracts 2004;22:3002.
4. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, et al.: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol 2004;22:777-784. (Pubitemid 41103588)
5. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, et al.: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004;22:785-794. (Pubitemid 41103589)
6. Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, et al.: TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892-5899.
7. Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, De Rosa F, et al.: Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007;25:1545-1552. (Pubitemid 46733081)
8. Yoshimura M, Nakamura S, Imamura F, Ueno K, Yamamoto S, Igarashi T, et al.: Severe myelotoxicity in a combination of gefitinib and vinorelbine. Lung Cancer 2004;45:121-123. (Pubitemid 38757840)
9. Pujol JL, Viens P, Rebattu P, Laurie SA, Feld R, Deneulin A, et al.: Gefitinib (IRESSA) with vinorelbine or vinorelbine/cisplatin for chemotherapy-naive non-small cell lung cancer patients. J Thorac Oncol 2006;1:417-424. (Pubitemid 47181417)
10. Davies AM, Ho C, Beckett L, Lau D, Scudder SA, Lara PN, et al.: Intermittent erlotinib in combination with pemetrexed: phase I schedules designed to achieve pharmacodynamic separation. J Thorac Oncol 2009;4:862-868.
11. Pao W, Chmielecki J: Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 2010;10:760-774.